Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation

Beom Kyung Kim, Kyung Ah Kim, Jun Yong Park, Sang Hoon Ahn, Chae Yoon Chon, Kwang Hyub Han, Seung Up Kim, Myeong Jin Kim

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Backgrounds: European Association for the Study of the Liver (EASL) and modified Response Evaluation Criteria in Solid Tumours (mRECIST) guidelines, which measure changes in arterialised hepatocellular carcinoma (HCC), differ in terms of number of target lesions (all versus ≤2) and calculation method (bidimensional versus unidimensional). We compared prognostic values of mRECIST for predicting overall survival (OS) with reference to EASL criteria in treatment-naïve HCC undergoing trans-arterial chemoembolisation (TACE). Methods: The ability to predict OS during longitudinal follow-up was expressed as C-index, and a sample size of 292 patients was required to validate its equivalence between each criteria. Treatment responses were assessed using both guidelines 4 weeks after the first TACE, using dynamic computed tomography or magnetic resonance imaging. Kaplan-Meier and Cox regression analyses were used to explore differences in OS between responders (complete or partial) and non-responders (stable or progressive disease), defined by each method. Results: C-index for EASL and mRECIST guidelines was 0.753 and 0.759, respectively, demonstrating equivalence between two methods. Differences in median OS between responders and non-responders were statistically significant for both EASL (30.1 versus 18.7 months, p < 0.001) and mRECIST (33.8 versus 17.1 months, p < 0.001) guidelines. In addition to radiological response, α-fetoprotein (p < 0.001), tumour number (p < 0.001) and tumour size (p = 0.048) were significant predictors of OS. In multivariate analysis, radiological criteria, tumour number and α-fetoprotein were identified as independent predictors (all p < 0.05). Conclusion: mRECIST, a simpler method, provided prognostic values for predicting OS equivalent to EASL criteria in patients with HCC undergoing TACE as an initial treatment modality.

Original languageEnglish
Pages (from-to)826-834
Number of pages9
JournalEuropean Journal of Cancer
Volume49
Issue number4
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

Hepatocellular Carcinoma
Survival
Guidelines
Fetal Proteins
Liver
Neoplasms
Sample Size
Response Evaluation Criteria in Solid Tumors
Therapeutics
Multivariate Analysis
Tomography
Regression Analysis
Magnetic Resonance Imaging

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{38cec934b9da403fb192ddac3c6c8168,
title = "Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation",
abstract = "Backgrounds: European Association for the Study of the Liver (EASL) and modified Response Evaluation Criteria in Solid Tumours (mRECIST) guidelines, which measure changes in arterialised hepatocellular carcinoma (HCC), differ in terms of number of target lesions (all versus ≤2) and calculation method (bidimensional versus unidimensional). We compared prognostic values of mRECIST for predicting overall survival (OS) with reference to EASL criteria in treatment-na{\"i}ve HCC undergoing trans-arterial chemoembolisation (TACE). Methods: The ability to predict OS during longitudinal follow-up was expressed as C-index, and a sample size of 292 patients was required to validate its equivalence between each criteria. Treatment responses were assessed using both guidelines 4 weeks after the first TACE, using dynamic computed tomography or magnetic resonance imaging. Kaplan-Meier and Cox regression analyses were used to explore differences in OS between responders (complete or partial) and non-responders (stable or progressive disease), defined by each method. Results: C-index for EASL and mRECIST guidelines was 0.753 and 0.759, respectively, demonstrating equivalence between two methods. Differences in median OS between responders and non-responders were statistically significant for both EASL (30.1 versus 18.7 months, p < 0.001) and mRECIST (33.8 versus 17.1 months, p < 0.001) guidelines. In addition to radiological response, α-fetoprotein (p < 0.001), tumour number (p < 0.001) and tumour size (p = 0.048) were significant predictors of OS. In multivariate analysis, radiological criteria, tumour number and α-fetoprotein were identified as independent predictors (all p < 0.05). Conclusion: mRECIST, a simpler method, provided prognostic values for predicting OS equivalent to EASL criteria in patients with HCC undergoing TACE as an initial treatment modality.",
author = "Kim, {Beom Kyung} and Kim, {Kyung Ah} and Park, {Jun Yong} and Ahn, {Sang Hoon} and Chon, {Chae Yoon} and Han, {Kwang Hyub} and Kim, {Seung Up} and Kim, {Myeong Jin}",
year = "2013",
month = "3",
day = "1",
doi = "10.1016/j.ejca.2012.08.022",
language = "English",
volume = "49",
pages = "826--834",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation

AU - Kim, Beom Kyung

AU - Kim, Kyung Ah

AU - Park, Jun Yong

AU - Ahn, Sang Hoon

AU - Chon, Chae Yoon

AU - Han, Kwang Hyub

AU - Kim, Seung Up

AU - Kim, Myeong Jin

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Backgrounds: European Association for the Study of the Liver (EASL) and modified Response Evaluation Criteria in Solid Tumours (mRECIST) guidelines, which measure changes in arterialised hepatocellular carcinoma (HCC), differ in terms of number of target lesions (all versus ≤2) and calculation method (bidimensional versus unidimensional). We compared prognostic values of mRECIST for predicting overall survival (OS) with reference to EASL criteria in treatment-naïve HCC undergoing trans-arterial chemoembolisation (TACE). Methods: The ability to predict OS during longitudinal follow-up was expressed as C-index, and a sample size of 292 patients was required to validate its equivalence between each criteria. Treatment responses were assessed using both guidelines 4 weeks after the first TACE, using dynamic computed tomography or magnetic resonance imaging. Kaplan-Meier and Cox regression analyses were used to explore differences in OS between responders (complete or partial) and non-responders (stable or progressive disease), defined by each method. Results: C-index for EASL and mRECIST guidelines was 0.753 and 0.759, respectively, demonstrating equivalence between two methods. Differences in median OS between responders and non-responders were statistically significant for both EASL (30.1 versus 18.7 months, p < 0.001) and mRECIST (33.8 versus 17.1 months, p < 0.001) guidelines. In addition to radiological response, α-fetoprotein (p < 0.001), tumour number (p < 0.001) and tumour size (p = 0.048) were significant predictors of OS. In multivariate analysis, radiological criteria, tumour number and α-fetoprotein were identified as independent predictors (all p < 0.05). Conclusion: mRECIST, a simpler method, provided prognostic values for predicting OS equivalent to EASL criteria in patients with HCC undergoing TACE as an initial treatment modality.

AB - Backgrounds: European Association for the Study of the Liver (EASL) and modified Response Evaluation Criteria in Solid Tumours (mRECIST) guidelines, which measure changes in arterialised hepatocellular carcinoma (HCC), differ in terms of number of target lesions (all versus ≤2) and calculation method (bidimensional versus unidimensional). We compared prognostic values of mRECIST for predicting overall survival (OS) with reference to EASL criteria in treatment-naïve HCC undergoing trans-arterial chemoembolisation (TACE). Methods: The ability to predict OS during longitudinal follow-up was expressed as C-index, and a sample size of 292 patients was required to validate its equivalence between each criteria. Treatment responses were assessed using both guidelines 4 weeks after the first TACE, using dynamic computed tomography or magnetic resonance imaging. Kaplan-Meier and Cox regression analyses were used to explore differences in OS between responders (complete or partial) and non-responders (stable or progressive disease), defined by each method. Results: C-index for EASL and mRECIST guidelines was 0.753 and 0.759, respectively, demonstrating equivalence between two methods. Differences in median OS between responders and non-responders were statistically significant for both EASL (30.1 versus 18.7 months, p < 0.001) and mRECIST (33.8 versus 17.1 months, p < 0.001) guidelines. In addition to radiological response, α-fetoprotein (p < 0.001), tumour number (p < 0.001) and tumour size (p = 0.048) were significant predictors of OS. In multivariate analysis, radiological criteria, tumour number and α-fetoprotein were identified as independent predictors (all p < 0.05). Conclusion: mRECIST, a simpler method, provided prognostic values for predicting OS equivalent to EASL criteria in patients with HCC undergoing TACE as an initial treatment modality.

UR - http://www.scopus.com/inward/record.url?scp=84873713980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873713980&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2012.08.022

DO - 10.1016/j.ejca.2012.08.022

M3 - Article

C2 - 22995582

AN - SCOPUS:84873713980

VL - 49

SP - 826

EP - 834

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -